AAMU
TEVA icon

Amundi Asset Management US’s Teva Pharmaceuticals TEVA Stock Holding History

Amundi Asset Management US’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		$2.6M Buy
225,185
+2,009
+0.9% +$23K ﹤0.01% 1151
2020
Q4 		$2.15M Buy
223,176
+16,309
+8% +$156K ﹤0.01% 1122
2020
Q3 		$1.86M Buy
206,867
+59,928
+41% +$634K ﹤0.01% 1107
2020
Q2 		$1.81M Buy
146,939
+37,726
+35% +$427K ﹤0.01% 1095
2020
Q1 		$981K Sell
109,213
-18,126
-14% -$186K ﹤0.01% 1100
2019
Q4 		$1.25M Buy
127,339
+26,028
+26% +$232K ﹤0.01% 1205
2019
Q3 		$697K Sell
101,311
-4,400
-4% -$33.7K ﹤0.01% 1280
2019
Q2 		$976K Buy
105,711
+3,950
+4% +$47.6K ﹤0.01% 1257
2019
Q1 		$1.6M Buy
101,761
+9,571
+10% +$169K ﹤0.01% 1135
2018
Q4 		$1.42K Buy
92,190
+18,324
+25% +$376K ﹤0.01% 1100
2018
Q3 		$1.59M Buy
73,866
+1,369
+2% +$31.8K ﹤0.01% 1179
2018
Q2 		$1.76M Buy
72,497
+1,297
+2% +$26.4K ﹤0.01% 1147
2018
Q1 		$1.22M Buy
71,200
+12,158
+21% +$237K ﹤0.01% 1157
2017
Q4 		$1.12M Buy
+59,042
New +$888K ﹤0.01% 1189
2016
Q1 		– Sell
-354,962
Closed -$23.3M – 578
2015
Q4 		$23.3M Sell
354,962
-1,284,267
-78% -$79.4M 0.09% 196
2015
Q3 		$92.6M Buy
1,639,229
+483,763
+42% +$31.4M 0.38% 75
2015
Q2 		$68.3M Buy
1,155,466
+7,888
+0.7% +$487K 0.25% 113
2015
Q1 		$71.5M Buy
1,147,578
+111,857
+11% +$6.5M 0.26% 106
2014
Q4 		$59.6M Buy
1,035,721
+797,760
+335% +$44.4M 0.22% 125
2014
Q3 		$12.8M Buy
237,961
+10,196
+4% +$540K 0.05% 307
2014
Q2 		$11.9M Buy
227,765
+209,947
+1,178% +$10.7M 0.05% 315
2014
Q1 		$942K Sell
17,818
-60,600
-77% -$2.8M ﹤0.01% 581
2013
Q4 		$3.14M Sell
78,418
-772,960
-91% -$30.4M 0.01% 501
2013
Q3 		$32.2M Buy
851,378
+88,907
+12% +$3.47M 0.13% 186
2013
Q2 		$29.9M Buy
+762,471
New +$29.7M 0.12% 200

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Amundi Asset Management US's TEVA Position: Q1 2021 in Review

Amundi Asset Management US increased its Teva Pharmaceuticals (TEVA) stake by 0.9% in Q1 2021, buying an estimated $23K and bringing the position to 225,185 shares worth $2.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1151.

Amundi Asset Management US first reported a position in TEVA in Q2 2013 and has held it in 25 quarters since. The position peaked at $92.6M in Q3 2015. 451 funds tracked by Wall St. Rank hold TEVA as of Q1 2021.

  • Amundi Asset Management US held 225,185 shares of Teva Pharmaceuticals worth $2.6M as of Q1 2021.
  • Amundi Asset Management US bought 2,009 Teva Pharmaceuticals shares in Q1 2021, an estimated $23K.
  • Teva Pharmaceuticals made up ﹤0.01% of Amundi Asset Management US's portfolio in Q1 2021, its #1151 holding.
  • Amundi Asset Management US first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 25 quarters since.
  • Amundi Asset Management US's Teva Pharmaceuticals position peaked at $92.6M in Q3 2015.
  • 451 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2021.

Based on Amundi Asset Management US's 13F filing for Q1 2021, filed 17 May 2021.